Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib plus sintilimab for later-line treatment of left- vs right-sided metastatic colorectal cancer
ChiCTR2500109899Phase 4Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of regorafenib and sintilimab in colorectal adenocarcinoma, sponsored by Chongqing University Cancer Hospital. Primary endpoint: Overall survival. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
regorafenibsintilimab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500109899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109899.